Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CNR2 | P34972 | 9/20 | 0.56 |
| ▸ | CNR1 | P21554 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5245640 | 0.97 | CNR2 (0.60) | LMNACNR2CNR1KMT2AHPGD | |
| SCHEMBL4141591 | 0.93 | LMNA (0.61) | LMNACNR2CNR1KMT2AHPGD | |
| SCHEMBL3006908 | 0.92 | LMNA (0.57) | LMNACNR2CNR1KMT2AHPGD | |
| SCHEMBL2989308 | 0.90 | LMNA (0.55) | LMNACNR2CNR1KMT2AHPGD | |
| SCHEMBL3004121 | 0.90 | LMNA (0.60) | LMNACNR2CNR1KMT2AHPGD | |
| SCHEMBL13048082 | 0.89 | LMNA (0.58) | LMNACNR2CNR1KMT2AHPGD | |
| SCHEMBL1429954 | 0.88 | LMNA (0.74) | LMNACNR2CNR1KMT2AHPGD | |
| SCHEMBL1431209 | 0.88 | LMNA (0.57) | LMNACNR2CNR1KMT2AHPGD | |
| SCHEMBL2991257 | 0.87 | LMNA (0.56) | LMNACNR2CNR1KMT2AHPGD | |
| SCHEMBL27789854 | 0.86 | CNR2 (0.59) | LMNACNR2CNR1HPGDPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102199-B1 | ANTIBACTERIAL POLYCYCLIC UREA COMPOUNDS | ASTRAZENECA AB (SE) | 2011-04-27 | — | — | EP | disclosed |
| US-7674801-B2 | Alkyl urea substituted pyridines | ASTRAZENECA AB (SE) | 2010-03-09 | — | — | US | disclosed |
| US-20090170791-A1 | MACROLONES | GLAXO SMITH KLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O A CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090170791-A1 | MACROLONES | GLAXO SMITH KLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O A CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090170791-A1 | MACROLONES | GLAXO SMITH KLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O A CORPORATION | 2009-07-02 | — | — | US | disclosed |
| EP-1945652-A1 | MACROLONES | GLAXO GROUP LIMITED (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20080132546-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| WO-2007054296-A1 | MACROLONES | GLAXO GROUP LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
| CN-1161336-C | Quinoline carboxamides as antiviral agents | �������Ŷ���Լ��������˾ | 2004-08-11 | — | — | CN | disclosed |
| CN-1333753-A | Quinoline carboxamides as antiviral agents | UPJOHN CO (US) | 2002-01-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132546-A1 | CHEMICAL COMPOUNDS | MRPL21, NISCH, ABCB11 | LMNA 3493/4885CNR2 1812/4885CNR1 1457/4885 |
| US-20090170791-A1 | MACROLONES | CYP51A1, MRPL21, LSS | LMNA 1071/4885CNR2 4651/4885CNR1 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.